VIDEO: AML responds to ivosidenib with venetoclax and azacytidine
In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a study presented at ASCO21 that looked at the combination of ivosidenib and venetoclax with and without azacitidine for acute myeloid leukemia.
The phase 1b/2 study evaluated 25 patients with newly diagnosed AML or relapsed/refractory AML.
"Well over 70% of patients had a significant response and there were a significant number of complete responses too," Gerds said.
"The question here is will this add on to the toxicity? Because azacitidine plus venetoclax does come with some toxicity including febrile neutropenia, pneumonitis, and fungal infections," he said.
Collapse
Lachowiez C.A. et al. Abstract 7012. Presented at: ASCO Annual Meeting (virtual meeting); 2021; June 4-8, 2021.